In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

EMA has recommended Ablymico and Liraglutide STADA and an oral formulation of Wegovy, potentially expanding GLP-1 treatment ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD ...

SAN DIEGO -- A 1-mg dose of semaglutide (Wegovy) weekly was better at maintaining weight than 3-mg liraglutide (Saxenda) daily for patients who put on pounds after bariatric surgery, a retrospective ...

Results from a randomized, double-blind trial in diabetes-free adults living with obesity and high cardiovascular disease risk showed that liraglutide was associated with a reduction in both muscle ...

An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide slashed ...

New trial shows liraglutide helps reduce BMI in children aged 6 to 12 with obesity, but side effects prompt further study Study: Liraglutide for Children 6 to <12 Years of Age with Obesity — A ...

Share on Pinterest Can a GLP-1 drug help protect against cognitive decline? Early trials say ‘yes.’ Image credit: Halfpoint Images/Getty Images. Over the last year, the use of and interest in glucagon ...

To investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. This ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it ...